Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results , with sales up 17.2% year on year to $794 ...

Q1 2025 Management View CEO Martine Rothblatt highlighted that United Therapeutics achieved record revenue for the quarter, marking the ninth such achievement in the past 12 quarters. She emphasized ...

FDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $6.29 per share. The drugmaker posted revenue of $794.4 ...

Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today. All participants on the ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. United Therapeutics met analysts’ revenue expectations last ...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

United Therapeutics Corporation (UTHR) reported its first-quarter 2025 earnings, showcasing a strong financial performance that exceeded market expectations. The company posted an earnings per ...

United Therapeutics maintained a strong balance sheet, with $5.03 billion in cash and investments as of March 31, 2025. The company will host a conference call later today to discuss the quarter in ...